[go: up one dir, main page]

NO20042822L - Forlenget frigjoring - farmasoytisk tablett av metformin - Google Patents

Forlenget frigjoring - farmasoytisk tablett av metformin

Info

Publication number
NO20042822L
NO20042822L NO20042822A NO20042822A NO20042822L NO 20042822 L NO20042822 L NO 20042822L NO 20042822 A NO20042822 A NO 20042822A NO 20042822 A NO20042822 A NO 20042822A NO 20042822 L NO20042822 L NO 20042822L
Authority
NO
Norway
Prior art keywords
metformin
extended release
released
hours
pharmaceutical tablet
Prior art date
Application number
NO20042822A
Other languages
English (en)
Other versions
NO333929B1 (no
Inventor
Benoit Schmitt
Pawan Seth
Original Assignee
Valeant Internat Bermuda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valeant Internat Bermuda filed Critical Valeant Internat Bermuda
Publication of NO20042822L publication Critical patent/NO20042822L/no
Publication of NO333929B1 publication Critical patent/NO333929B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NO20042822A 2001-12-04 2004-07-02 Forlenget frigjøring - farmasøytisk tablett av metformin NO333929B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/005,387 US20030118647A1 (en) 2001-12-04 2001-12-04 Extended release tablet of metformin
PCT/US2002/038599 WO2003047529A2 (en) 2001-12-04 2002-12-04 Extended release pharmaceutical tablet of metformin

Publications (2)

Publication Number Publication Date
NO20042822L true NO20042822L (no) 2004-08-26
NO333929B1 NO333929B1 (no) 2013-10-21

Family

ID=21715581

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20042822A NO333929B1 (no) 2001-12-04 2004-07-02 Forlenget frigjøring - farmasøytisk tablett av metformin
NO20130984A NO20130984L (no) 2001-12-04 2013-07-16 Forlenget frigjøring - farmasøytisk tablett av metformin

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20130984A NO20130984L (no) 2001-12-04 2013-07-16 Forlenget frigjøring - farmasøytisk tablett av metformin

Country Status (12)

Country Link
US (3) US20030118647A1 (no)
EP (1) EP1460998B1 (no)
AT (1) ATE460157T1 (no)
AU (1) AU2002359582C1 (no)
CA (1) CA2470747C (no)
DE (1) DE60235648D1 (no)
ES (1) ES2338536T3 (no)
HU (1) HU229962B1 (no)
MX (1) MXPA04005667A (no)
NO (2) NO333929B1 (no)
NZ (1) NZ533857A (no)
WO (1) WO2003047529A2 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1322158T3 (da) * 2000-10-02 2012-11-19 Usv Ltd Farmaceutiske præparater med langvarig frigivelse, som indeholder metformin, og fremgangsmåde til fremstilling deraf
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
ES2377729T3 (es) * 2002-02-21 2012-03-30 Valeant International (Barbados) Srl Formulaciones de liberación modificada de al menos una forma de tramadol
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
KR100897890B1 (ko) 2002-06-17 2009-05-18 인벤티아 헬스케어 피브이티. 엘티디. 티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) * 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20080181946A1 (en) * 2004-05-14 2008-07-31 Braj Bhushan Lohray Controlled Release Delivery System For Metformin
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
EP2623099A1 (en) 2004-11-24 2013-08-07 Neuromolecular Pharmaceuticals, Inc Composition and method for treating neurological disease
KR100780553B1 (ko) * 2005-08-18 2007-11-29 한올제약주식회사 메트포르민 서방정 및 그의 제조방법
KR100858848B1 (ko) * 2006-05-23 2008-09-17 한올제약주식회사 메트포르민 서방정
PL2596784T3 (pl) * 2007-11-23 2017-06-30 Grünenthal GmbH Kompozycje tapentadolu
WO2010026467A2 (en) * 2008-09-04 2010-03-11 Torrent Pharmaceuticals Ltd. Controlled release dosage form of high solubility active ingredient
JP5885668B2 (ja) * 2009-12-02 2016-03-15 アダマス ファーマシューティカルズ， インコーポレイテッド アマンタジン組成物および使用方法
HUE042593T2 (hu) * 2010-03-09 2019-07-29 Alkermes Pharma Ireland Ltd Alkoholnak ellenálló enterális gyógyszerkészítmények
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
CN103622930B (zh) * 2013-12-19 2015-06-10 石家庄市华新药业有限责任公司 一种盐酸二甲双胍缓释制剂及其制备方法
WO2016042567A1 (en) * 2014-09-16 2016-03-24 Suresh Pareek Extended release formulation of metformin
WO2019186420A1 (en) * 2018-03-29 2019-10-03 Tata Chemicals Limited Encapsulated micronutrient granules for fortification of edible salt compositions

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2001A (en) * 1841-03-12 Sawmill
US4721709A (en) * 1984-07-26 1988-01-26 Pyare Seth Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
CH672888A5 (no) * 1986-11-07 1990-01-15 Mepha Ag
CH668553A5 (de) * 1987-02-02 1989-01-13 Mepha Ag Arzneimittel mit verzoegerter wirkstofffreisetzung.
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
FR2723536A1 (fr) * 1994-08-11 1996-02-16 Seth Pawan Composition permettant une liberation selective d'un principe actif
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US6348469B1 (en) * 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
US6117453A (en) * 1995-04-14 2000-09-12 Pharma Pass Solid compositions containing polyethylene oxide and an active ingredient
JP3463266B2 (ja) * 1995-09-21 2003-11-05 ファーマ パス エルエルシー 酸不安定性オメパラゾールを含有する新規組成物及びその製造方法
US6048547A (en) * 1996-04-15 2000-04-11 Seth; Pawan Process for manufacturing solid compositions containing polyethylene oxide and an active ingredient
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
DE19915420A1 (de) * 1999-04-06 2000-10-12 Basf Ag Stabilisierte Polyvinylpyrrolidon-Zubereitungen
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
US6338857B1 (en) * 2000-05-26 2002-01-15 Pharma Pass Llc Sustained release carbamazepine pharmaceutical composition free of food effect and a method for alleviating food effect in drug release
US6350471B1 (en) * 2000-05-31 2002-02-26 Pharma Pass Llc Tablet comprising a delayed release coating
US20030021841A1 (en) * 2001-07-02 2003-01-30 Matharu Amol Singh Pharmaceutical composition

Also Published As

Publication number Publication date
EP1460998A2 (en) 2004-09-29
AU2002359582C1 (en) 2008-11-13
CA2470747C (en) 2009-07-28
AU2002359582A1 (en) 2003-06-17
NO333929B1 (no) 2013-10-21
HUP0500004A2 (hu) 2005-04-28
EP1460998B1 (en) 2010-03-10
US20030170302A1 (en) 2003-09-11
WO2003047529A3 (en) 2003-10-30
HUP0500004A3 (en) 2012-09-28
CA2470747A1 (en) 2003-06-12
US20030118647A1 (en) 2003-06-26
US20040161461A1 (en) 2004-08-19
DE60235648D1 (de) 2010-04-22
MXPA04005667A (es) 2005-06-17
ATE460157T1 (de) 2010-03-15
HU229962B1 (hu) 2015-03-30
ES2338536T3 (es) 2010-05-10
EP1460998A4 (en) 2005-09-14
NO20130984L (no) 2004-08-26
AU2002359582B2 (en) 2007-01-18
WO2003047529A2 (en) 2003-06-12
NZ533857A (en) 2007-05-31

Similar Documents

Publication Publication Date Title
NO20042822L (no) Forlenget frigjoring - farmasoytisk tablett av metformin
NO20022987L (no) Dual-frigivende sammensetninger av en cyclooksygenase-2 inhibitor
BR9908438A (pt) Tabletes de desintegração rápida
DE59802670D1 (de) Osmotisches arzneimittelfreisetzungssystem
SE9704869D0 (sv) New pharmaceutical formulaton II
WO2003072025A3 (en) Modified release formulations of at least one form of tramadol
PE20030527A1 (es) Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
DOP2013000023A (es) Un compuesto seleccionado del acido 6-(4-bromo-2-cloro-fenilamino) -7-fluror-3-metil-3h-benzoimidazol -5-carboxilico (2-hidroxi-etoxi)-amida y sales farmaceuticamente aceptables del mismo, y composiciones farmaceuticas que contienen dicho compuesto
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
HRP20040996B1 (hr) Tablete visokog sadržaja lijeka
DK1113787T3 (da) Agitationsuafhængige farmaceutiske multipelenhedsretardformuleringer og fremgangsmåde til deres fremstilling
DK1293196T3 (da) Farmaceutisk præparat der omfatter doxazosin
ES2176106B1 (es) Comprimido matricial de liberacion prolongada de trimetazidina tras su administracion por via oral.
IS2691B (is) Áætlun um lyfjaskammta og lyfjasamsetningar til getnaðarvarnar í neyð
GB0012362D0 (en) Chemical compounds
DK1678162T3 (da) P-glycoprotein-inhibitor, fremgangsmåde til fremstilling heraf og farmaceutisk sammensætning omfattende denne
AR036658A1 (es) Formulacion de dosificacion oral de fundicion instantanea
AR014012A1 (es) Formula de liberacion prolongada
WO2003005967A3 (en) Dual release levodopa ethyl ester and decarboxylase in controlled release core
PT1425005E (pt) Composicao farmaceutica que compreende lumiracoxib
MXPA04003346A (es) Formulacion de dosis oral de disolucion instantanea.
SE9003904D0 (sv) Method for the manufacture of a pharmaceutical dosage form
MXPA04007437A (es) Sistema de suministro osmotico.
NO996049D0 (no) Kontrollert-frigjøring farmasoeytisk preparat med ACE inhibitor som aktivt middel
WO2003041656A3 (en) Soluble drug extended release system

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: VALEANT INTERNATIONAL BERMUD, BM

MM1K Lapsed by not paying the annual fees